Cutting Cost in Medicare: How About Considering Cost First?
This article was originally published in RPM Report
A modest proposal for the austerity era: let the federal government factor cost into coverage decisions for Medicare Part B. For biopharma companies, that sounds like a terrible idea—but, in the long term, the alternatives just might be much worse.
You may also be interested in...
FDA’s June Avastin hearing featured a number of points of clear disconnect between the sponsor, the agency, and other stakeholders debating the role of the therapy for metastatic breast cancer. Perhaps the biggest: the most important issue may depend on a completely different agency, CMS.
On July 21, Roche reported strong first half sales of Lucentis. It was all downhill from there.
A Medicare advisory committee brought few surprises for Dendreon’s prostate cancer therapy Provenge. Will CMS provide full coverage for Provenge or will it restrict use through coverage with evidence development?